London’s Kiin Bio Gets €1.9M In Pre- Seed Round To launch Its Drug Discovery Platform

The round was led by b2venture, with support from Heartfelt, rule30, and several strategic angel investors. The funding will help Kiin Bio grow its customer base, improve its AI technology, and expand its team.

“The future of drug discovery isn’t just better tools and data, it’s smarter integration. We see a future where an AI-driven Platform unifies this fragmented landscape, turning thousands of disjointed solutions into a cohesive engine for breakthroughs,” said Filippo Abbondanza, CEO and Co-founder of Kiin Bio. “We’re happy to have won such renowned investors who back our mission to build the pioneering Virtual Scientist Platform for drug discovery.”

With support from investors and ongoing pilot programs through its Frontier Programme, Kiin Bio aims to streamline the entire drug discovery process and drive faster, smarter innovation.

The Kiin Bio team brings deep expertise across AI, bioinformatics, cloud infrastructure, and drug discovery. CEO Filippo Abbondanza holds a PhD in Bioinformatics and was formerly Product Director at Lifebit, where he helped build and scale AI-driven platforms for the pharma sector.

Read Also - British Startup OBT Live Secures €2.6 Million In Series A Round

Chief Data and Scientific Officer Mark Davies has over 20 years of experience in life sciences technology, having served as SVP Informatics & Data at Benevolent AI and as a technical leader at EMBL-EBI, where he developed major biomedical resources like ChEMBL and SureChEMBL.

CTO Bogdan Urse is a cloud infrastructure specialist with more than a decade of experience in building large-scale digital systems across cloud platforms, and he also previously worked at Lifebit.

Kiin Bio aims to solve one of the biggest problems in drug discovery—the expensive and disconnected R&D process, which can take up to 3.7 million hours and involve hundreds of scientists to develop just one drug.

The company estimates that the drug discovery GenAI market could generate up to €96 million in the coming years. While many individual tools exist to support researchers, Kiin Bio sees a major gap: there’s no single platform that brings everything together, leading to lost productivity.

To fix this, Kiin Bio is building an all-in-one platform that streamlines the entire journey from discovery to development. Through its Frontier Programme, the startup has already launched three pilot projects, secured three commercial partnerships, and received a European grant from the ELSA Industry Awards for its AI innovation.

“Kiin Bio is building the missing layer in BioTech: an AI-native agentic infrastructure that redefines how drug discovery is done, tackling a huge global, and fragmented market. Their groundbreaking approach of orchestrating all relevant tools and solutions into a cohesive Virtual Scientist Platform is bold, timely, and transformative”, said Andreas Goeldi, Partner at b2venture. “We’re excited to be backing this strong team. Right from the start we have been impressed by their unique blend of scientific depth, technical execution and business acumen.”

About Kiin Bio

Founded in 2024, Kiin Bio is developing an AI-powered Virtual Scientist Platform to simplify and speed up drug discovery. The platform brings together virtual scientists, a smart marketplace, and scalable tech to handle everything from research and bioinformatics to lab work.